Evidence map›Paper›PMID 42282726›Full record

ArticlebioRxiv : the preprint server for biology2026

Overcoming host immune responses to an AAV-delivered HIV-1 bNAb in rhesus macaques mediated by co-delivery of PD-L1.

Michael Kuipa, Abubakarr A Koroma, Isai Leguizamo, Priya Dhole, Yash Barot, Michelle Y-H Lee, Gregory K Tharp, Shan Liang, Magdalen Chouinard, Stephanie Ehnert and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Michael KuipaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Abubakarr A KoromaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Isai LeguizamoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Priya DholeDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Yash BarotDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Michelle Y-H LeeDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Gregory K TharpDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Shan LiangDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Magdalen ChouinardDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Stephanie EhnertDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Stacey WeissmanDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Casey WhiteheadDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Rachelle L StammenDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Jennifer S WoodDivision of Animal Resources, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Elizabeth H CurranDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Deepa MachiahDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Evan D DessasauDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Yoshiaki NishimuraLaboratory of Immunoregulation and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Jun XieHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA USA.
Guangping GaoHorae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA USA.
Sumit VermaDepartment of Pediatrics Neurology and Neurosciences, Children's Healthcare of Atlanta, and Emory University School of Medicine, Atlanta, Georgia USA.
Deanna A KulpaDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Ian N MooreDivision of Pathology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Steven E BosingerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.
Matthew R GardnerDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia USA.ORCID 0000-0003-2872-7597

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2018 to 2026
$17.5M
Optimizing AAV delivery of bNAbs for HIV preventionR01AI167724 · NIAID · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2022 to 2026
$4.5M
AAV-delivered HIV inhibitors for SHIV therapyR01DA056770 · NIDA · EMORY UNIVERSITY · PI Matthew Ryan Gardner · 2022 to 2026
$4.1M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI167724NIDA NIH HHS R01 DA056770NIH HHS P51 OD011132NIH HHS S10 OD026799NIH HHS U42 OD011023
6 · The paper itself

Abstract

Adeno-associated virus (AAV)-delivered anti-HIV-1 broadly neutralizing antibodies (bNAbs) have demonstrated promise for preventing and treating HIV-1 infection in preclinical models. However, host immune responses, specifically anti-drug antibodies (ADA), limit sustained bNAb expression. We have previously shown that PD-L1-mediated immune shielding improves the consistency of AAV-delivered bNAb 3BNC117 expression from muscle tissue in rhesus macaques. Here, we test the breadth of this approach with another bNAb, 10-1074. We show that AAV9.PD-L1 co-delivery with AAV9.10-1074 reduced the occurrence of ADA responses and improved the durability of bNAb expression for one year post administration. Notably 12 of 12 macaques that received AAV9.10-1074 vectors were protected against ten repeated SHIV

Identifiers

PMID42282726
PMCPMC13251908

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.